Identification of circulating tumor DNA for the early detection of small-cell lung cancer
Avogbe, Patrice Hodonou
Delhomme, Tiffany M.
Le Calvez-Kelm, Florence
McKay, James D.
EBioMedicine, 2352-3964, Vol. 10, August, 2016, p.117-123
MetadataShow full item record
Circulating tumor DNA (ctDNA) is emerging as a key potential biomarker for post-diagnosis surveillance but it may also play a crucial role in the detection of pre-clinical cancer. Small-cell lung cancer (SCLC) is an excellent candidate for early detection given there are no successful therapeutic options for late-stage disease, and it displays almost universal inactivation of TP53. We assessed the presence of TP53 mutations in the cell-free DNA (cfDNA) extracted from the plasma of 51 SCLC cases and 123 non-cancer controls. We identified mutations using a pipeline specifically designed to accurately detect variants at very low fractions. We detected TP53 mutations in the cfDNA of 49% SCLC patients and 11.4% of non-cancer controls. When stratifying the 51 initial SCLC cases by stage, TP53 mutations were detected in the cfDNA of 35.7% early-stage and 54.1% late-stage SCLC patients. The results in the controls were further replicated in 10.8% of an independent series of 102 non-cancer controls. The detection of TP53 mutations in 11% of the 225 non-cancer controls suggests that somatic mutations in cfDNA among individuals without any cancer diagnosis is a common occurrence, and poses serious challenges for the development of ctDNA screening tests.
TopicsÁcidos nucleicos libres de células
ADN tumoral circulante
Carcinoma pulmonar de células pequeñas
Genes supresores de tumor
- Artículos 
The following license files are associated with this item: